Dafurag, zawiesina Dafurag_zawiesina_packshot_WWW_2019-05

Dafurag, zawiesina

Category Prescription medication

Additional information

Active substance

1 ml of suspension contains 10 mg of furazidin (Furazidinium) Well-known ingredients: sucrose, methyl parahydroxybenzoate (E218), propyl parahydroxybenzoate (E216), ethanol.


Treatment of acute and chronic uncomplicated lower urinary tract infections, caused by Escherichia coli bacteria in children and adults


Hypersensitivity to furazidin or any other product ingredients (listed in section 6) or to nitrofuran derivatives;
during the first three months of pregnancy;
during pregnancy carried to term (from week 38) and during delivery, due to the risk of haemolytic anemia (disintegration of red blood cells) in the infant;
in children up to 3 months of age;
in patients with renal failure;
in patients with a diagnosed polyneuropathy, e.g. caused by diabetes (damage of nerves caused by elevated blood sugar levels);
in patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency – the medicine may cause red blood cells to disintegrate (haemolysis), which in turn may be the cause of development of haemolytic anemia.

Marketing Authorisation Holder

Aflofarm Farmacja Polska Spółka z o.o.

Marketing Authorisation


Information for the patient

Read the leaflet for indications, contraindications, adverse events and dosage and information on the use of this medicinal product, or consult your doctor or pharmacist before taking any medicine that is misused or threatening your life or health.

See how we care about quality

All our products are subject to strict safety requirements

We use rigorous quality control standards and procedures to ensure the highest level of safety for all our products.

See how we care about safety